Engineering smart cells for arthritis therapy

工程智能细胞用于关节炎治疗

基本信息

  • 批准号:
    9912537
  • 负责人:
  • 金额:
    $ 39.28万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-09-15 至 2021-09-14
  • 项目状态:
    已结题

项目摘要

Abstract The primary aim of this project will be to apply recent development of genome editing technologies to generate a highly advanced “smart” tissue-engineered construct featuring cell-based, feedback control of gene expression as a means of autoregulated drug or growth factor delivery. An important advance of this system is that cells will be programmed to automatically regulate their activity in response to environmental signals. To engineer this regulatory system, the gene regulation circuitry of stem cells (iPSCs) will be rewired to form controlled feedback loops that are activated by external stimuli, but then induce a controlled and autoregulated response. These cells will be used to form tissue-engineered constructs for in vitro and in vivo testing. The initial focus of the project will be on the creation of designer stem cells that contain artificial gene circuits that provide anti-inflammatory drug delivery in response to the environment. These cells will be engineered into stable cartilage constructs that will be implanted as a therapeutic approach for the treatment of autoimmune diseases such as rheumatoid arthritis. The creation of “smart” cells that provide automated, long-term, feedback-controlled drug therapy represents a transformative paradigm for regenerative medicine and arthritis therapy.
摘要 该项目的主要目的是应用基因组编辑技术的最新发展, 一种高度先进的“智能”组织工程构建体,具有基于细胞的基因反馈控制功能, 表达作为自动调节药物或生长因子递送的手段。该系统的一个重要进步是 细胞将被编程以自动调节其活动以响应环境信号。到 工程师这个调控系统,干细胞(iPSC)的基因调控电路将重新连接,形成 受控反馈回路由外部刺激激活,但随后诱导受控和自动调节 反应这些细胞将用于形成用于体外和体内测试的组织工程构建体。的 该项目最初的重点将是创造含有人工基因电路的设计干细胞, 响应环境提供抗炎药物递送。这些细胞将被改造成 将作为治疗方法植入用于治疗自身免疫性关节炎的稳定的软骨构建体, 类风湿性关节炎等疾病。创造“智能”细胞,提供自动化,长期, 反馈控制的药物治疗代表了再生医学和关节炎的一个变革性范例 疗法

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Farshid Guilak其他文献

Farshid Guilak的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Farshid Guilak', 18)}}的其他基金

Synthetic Chronogenetic Gene Circuits for Circadian Cell Therapies
用于昼夜节律细胞疗法的合成计时基因电路
  • 批准号:
    10797183
  • 财政年份:
    2023
  • 资助金额:
    $ 39.28万
  • 项目类别:
2023 Cartilage Biology and Pathology Gordon Research Conference and Gordon Research Seminar
2023年软骨生物学与病理学戈登研究会议暨戈登研究研讨会
  • 批准号:
    10605625
  • 财政年份:
    2022
  • 资助金额:
    $ 39.28万
  • 项目类别:
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
  • 批准号:
    10532032
  • 财政年份:
    2022
  • 资助金额:
    $ 39.28万
  • 项目类别:
Deconstructing Cartilage Mechanotransduction by Piezo Channels
通过压电通道解构软骨机械传导
  • 批准号:
    10533155
  • 财政年份:
    2022
  • 资助金额:
    $ 39.28万
  • 项目类别:
SMART stem cells that autonomously down-modulate TFG-β signaling for Articular Cartilage Repair
SMART 干细胞自主下调 TFG-β 信号传导以修复关节软骨
  • 批准号:
    10371823
  • 财政年份:
    2022
  • 资助金额:
    $ 39.28万
  • 项目类别:
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
  • 批准号:
    10707979
  • 财政年份:
    2022
  • 资助金额:
    $ 39.28万
  • 项目类别:
Genetically-engineered stem cells for self-regulating arthritis therapy
用于自我调节关节炎治疗的基因工程干细胞
  • 批准号:
    10630757
  • 财政年份:
    2022
  • 资助金额:
    $ 39.28万
  • 项目类别:
Genetically-engineered stem cells for self-regulating arthritis therapy
用于自我调节关节炎治疗的基因工程干细胞
  • 批准号:
    10598619
  • 财政年份:
    2022
  • 资助金额:
    $ 39.28万
  • 项目类别:
Genetically-engineered stem cells for self-regulating arthritis therapy
用于自我调节关节炎治疗的基因工程干细胞
  • 批准号:
    10434316
  • 财政年份:
    2022
  • 资助金额:
    $ 39.28万
  • 项目类别:
SMART stem cells that autonomously down-modulate TFG-β signaling for Articular Cartilage Repair
SMART 干细胞自主下调 TFG-β 信号传导以修复关节软骨
  • 批准号:
    10590752
  • 财政年份:
    2022
  • 资助金额:
    $ 39.28万
  • 项目类别:

相似海外基金

Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10707830
  • 财政年份:
    2023
  • 资助金额:
    $ 39.28万
  • 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
  • 批准号:
    479728
  • 财政年份:
    2023
  • 资助金额:
    $ 39.28万
  • 项目类别:
    Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
  • 批准号:
    10884567
  • 财政年份:
    2023
  • 资助金额:
    $ 39.28万
  • 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
  • 批准号:
    10751964
  • 财政年份:
    2023
  • 资助金额:
    $ 39.28万
  • 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
  • 批准号:
    486321
  • 财政年份:
    2022
  • 资助金额:
    $ 39.28万
  • 项目类别:
    Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10676786
  • 财政年份:
    2022
  • 资助金额:
    $ 39.28万
  • 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10440970
  • 财政年份:
    2022
  • 资助金额:
    $ 39.28万
  • 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
  • 批准号:
    10642998
  • 财政年份:
    2022
  • 资助金额:
    $ 39.28万
  • 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10482465
  • 财政年份:
    2022
  • 资助金额:
    $ 39.28万
  • 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
  • 批准号:
    10191053
  • 财政年份:
    2020
  • 资助金额:
    $ 39.28万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了